

January 20, 2024

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor Plot No.C/1, 'G'Block Bandra- Kurla Complex Bandra East, Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
--	---

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on January 20, 2024.

Ref.: Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With regard to the captioned matter and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (“**Listing Regulations**”), this is to inform you that at the meeting of the Board of Directors of the Company, which commenced at 04:35 P.M. and concluded at 05:50 P.M. today i.e. January 20, 2024, the Board of Directors have, inter alia, approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023.

Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023 of the Financial Year 2023-24 are enclosed herewith.

The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to “**Limited Review**” and the same is enclosed herewith.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,
Yours Sincerely,

For Rossari Biotech Limited

PARUL
GUPTA

Digitally signed by
PARUL GUPTA
Date: 2024.01.20
17:51:17 +05'30'



Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED


(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruiti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite ATC Tyre Phase III, G.I.D.C Dahej, Village Galanda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-3505 03

 info@rossari.com

 www.rossari.com

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India

T +91 22 6626 2699

F +91 22 6626 2601

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **31 December 2023** and the year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Rossari Biotech Limited
Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 31 December 2022 and audit of standalone financial results for the year ended 31 March 2023 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP, Chartered Accountants, who have expressed unmodified conclusion vide their review report dated 4 February 2023 and unmodified opinion vide their audit report dated 29 April 2023, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No:001076N/N500013

**BHARAT
KOCHU
SHETTY**

Digitally signed by
BHARAT KOCHU SHETTY
Date: 2024.01.20
17:36:43 +05'30'

Bharat Shetty
Partner
Membership No:106815

UDIN:24106815BKFNIE4200

Place: Mumbai
Date: 20 January 2024

ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, 2nd Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818



STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

Rs. In million

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2023	30th September, 2023	31st December, 2022	31st December, 2023	31st December, 2022	31st March, 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	2,987.52	3,320.12	2,368.98	8,891.06	7,115.30	9,751.72
Other Income	21.29	19.64	2.48	54.29	12.79	35.98
Total Income	3,008.81	3,339.76	2,371.46	8,945.35	7,128.09	9,787.70
II EXPENSES						
Cost of materials consumed	1,509.25	1,868.90	1,221.41	4,582.04	4,357.79	5,539.58
Purchase of stock-in-trade	543.00	821.41	478.46	2,150.96	900.18	1,633.26
Changes in inventory of finished goods, work-in-progress and stock-in-trade	110.93	(174.40)	(20.72)	(160.23)	(122.36)	(129.72)
Employee benefit expenses	140.63	125.84	146.49	400.79	423.62	573.47
Finance costs	26.26	25.44	17.55	70.45	34.55	46.18
Depreciation and amortisation expenses	58.41	62.58	66.81	176.09	192.67	259.83
Other expenses	272.32	254.99	224.13	731.36	687.48	908.65
Total Expenses	2,660.80	2,984.76	2,134.13	7,951.46	6,473.93	8,831.25
III Profit before exceptional items and tax [I-II]	348.01	355.00	237.33	993.89	654.16	956.45
IV Exceptional items	-	-	-	-	-	-
V Profit before tax [III-IV]	348.01	355.00	237.33	993.89	654.16	956.45
VI Tax Expense						
Current tax charge	103.19	95.77	67.23	277.52	179.49	259.66
Deferred tax charge/(credit)	(10.60)	(4.55)	(4.52)	(18.40)	(7.84)	(17.11)
Total Tax Expense	92.59	91.22	62.71	259.12	171.65	242.55
VII Profit after tax [V-VI]	255.42	263.78	174.62	734.77	482.51	713.90
VIII Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	1.23	1.24	0.05	3.71	0.15	4.50
ii Income tax relating to items that will not be reclassified to profit or loss	(0.31)	(0.31)	(0.02)	(0.93)	(0.04)	(1.13)
B Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income/(loss)	0.92	0.93	0.03	2.78	0.11	3.37
IX Total comprehensive income (VII + VIII)	256.34	264.71	174.65	737.55	482.62	717.27
Paid up equity share capital (Face value of Rs 2 per share)	110.47	110.45	110.30	110.47	110.30	110.31
Other equity						8,476.65
X Earnings per equity share (in Rs.)						
Basic	4.62*	4.78*	3.17*	13.31*	8.76*	12.95
Diluted	4.61*	4.77*	3.15*	13.28*	8.72*	12.90

*Not annualized

RS



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 20th January, 2024.
2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. During the quarter ended 31st December, 2023, the Company has allotted 9,330 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
5. Figures for previous period have been regrouped wherever considered necessary.

For ROSSARI BIOTECH LIMITED



EDWARD MENEZES

Executive Chairman

DIN:00149205

Place : Mumbai

Date : 20th January, 2024



Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **31 December 2023** and the consolidated year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of four subsidiaries included in the Statement, whose financial results reflect total revenues of ₹ 2,640.32 million and ₹ 7,953.49 million, total net profit after tax of ₹ 158.39 million and ₹ 437.69 million and total comprehensive income of ₹ 158.32 million and ₹ 437.44 million, for the quarter and nine-months period ended on 31 December 2023, respectively, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of ₹ (0.79) million and ₹ (4.35) million and total comprehensive loss of ₹ (0.78) million and ₹ (4.32) million, for the quarter and nine-months period ended on 31 December 2023, respectively, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the interim financial information of a subsidiary, which has not been reviewed by its auditor, whose interim financial information reflects total revenues of ₹ Nil, net loss after tax of ₹ 0.00* and total comprehensive loss of ₹ 0.00*, for the quarter and nine-months period ended 31 December 2023, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.98 million and ₹ 4.23 million, and total comprehensive income of ₹ 0.98 million and ₹ 4.23 million for the quarter and nine-months period ended on 31 December 2023 respectively, in respect of a joint venture, based on their interim financial information, which have not been reviewed by its auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the aforesaid subsidiary and joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

*('0.00' denotes amounts less than Rs. Ten thousand)

Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

7. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 31 December 2022 and audit of consolidated financial results for the year ended 31 March 2023 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP, Chartered Accountants, who have expressed unmodified conclusion vide their review report dated 4 February 2023 and unmodified opinion vide their audit report dated 29 April 2023, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter.

For **Walker Chandiok & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

BHARAT

KOCHU SHETTY

Digitally signed by
BHARAT KOCHU SHETTY
Date: 2024.01.20
17:37:26 +05'30'

Bharat Shetty

Partner

Membership No:106815

UDIN:24106815BKFNIF5654

Place: Mumbai

Date: 20 January 2024

Rossari Biotech Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

Sr. No. Particulars

Subsidiaries	
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited (Formerly known as Rossari Personal Care Products Private Limited)
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited (Incorporated on 10 August 2023)
Joint Venture	
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
Associate	
1	Romakk Chemicals Private Limited

ROSSARI BIOTECH LIMITED
(AN ISO9001:2005 & 14001:2015 Certified Company)



Regd. Office : 201 A & B, 2nd Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

Particulars	Quarter ended			Nine months ended		Year Ended
	31st December, 2023	30th September, 2023	31st December, 2022	31st December, 2023	31st December, 2022	31st March, 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	4,637.69	4,834.68	3,892.69	13,578.43	12,494.15	16,558.81
Other Income	35.02	13.64	11.14	70.56	26.78	54.84
Total Income	4,672.71	4,848.32	3,903.83	13,648.99	12,520.93	16,613.65
II EXPENSES						
Cost of materials consumed	2,909.95	3,556.31	2,494.82	9,259.76	8,284.62	10,791.05
Purchase of stock-in-trade	253.04	289.39	144.84	884.58	747.34	1,048.51
Changes in inventories of finished goods, work-in-progress and stock-in-trade	66.80	(418.06)	84.26	(591.80)	(181.52)	(126.44)
Employee benefits expense	260.40	275.27	241.79	780.88	718.40	986.16
Finance costs	43.23	50.29	46.68	156.68	179.69	223.15
Depreciation and amortisation expenses	150.88	151.14	159.58	443.16	469.16	629.31
Other expenses	510.80	496.10	385.34	1,395.18	1,240.88	1,629.29
Total Expenses	4,195.10	4,400.44	3,557.31	12,328.44	11,458.57	15,181.03
III Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]	477.61	447.88	346.52	1,320.55	1,062.36	1,432.62
IV Share of profit/(loss) of joint venture and associate	0.20	0.20	0.19	(0.09)	7.52	9.57
V Profit before exceptional items and tax [III+IV]	477.81	448.08	346.71	1,320.46	1,069.88	1,442.19
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax [V-VI]	477.81	448.08	346.71	1,320.46	1,069.88	1,442.19
VIII Tax Expense						
Current tax charge	159.26	139.32	117.15	430.44	368.19	491.34
Deferred tax (credit)	(25.35)	(20.72)	(27.25)	(75.55)	(81.09)	(121.72)
Total Tax Expense	133.91	118.60	89.90	354.89	287.10	369.62
IX Profit after tax [VII-VIII]	343.90	329.48	256.81	965.57	782.78	1,072.57
X Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	1.12	1.13	(0.22)	3.38	(0.65)	3.97
ii Income tax relating to items that will not be reclassified to profit or loss	(0.27)	(0.30)	0.03	(0.85)	0.15	(0.97)
B Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income/(loss)	0.85	0.83	(0.19)	2.53	(0.50)	3.00
XI Total comprehensive income (IX + X)	344.75	330.31	256.62	968.10	782.28	1,075.57
Profit for the period/year attributable to						
Owners of the Company	343.90	329.48	256.81	965.57	782.78	1,072.57
Non Controlling Interest	-	-	-	-	-	-
	343.90	329.48	256.81	965.57	782.78	1,072.57
Other Comprehensive Income/(Loss) attributable to						
Owners of the Company	0.85	0.83	(0.19)	2.53	(0.50)	3.00
Non Controlling Interest	-	-	-	-	-	-
	0.85	0.83	(0.19)	2.53	(0.50)	3.00
Total Comprehensive Income attributable to						
Owners of the Company	344.75	330.31	256.62	968.10	782.28	1,075.57
Non Controlling Interest	-	-	-	-	-	-
	344.75	330.31	256.62	968.10	782.28	1,075.57
Paid up equity share capital (Face value of Rs 2.00 per share)	110.47	110.45	110.30	110.47	110.30	110.31
Other equity						9,041.35
Earnings per equity share (in Rs.)						
Basic	6.23*	5.97*	4.66*	17.49*	14.21*	19.46
Diluted	6.21*	5.95*	4.63*	17.45*	14.14*	19.38

*Not annualized



Handwritten signature/initials

Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 20th January, 2024.
2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. During the quarter ended 31st December, 2023, the Parent Company has allotted 9,330 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
5. Figures for previous period have been regrouped wherever considered necessary.

For ROSSARI BIOTECH LIMITED



EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai

Date : 20th January, 2024

